Cargando…
A Multiplexed Urinary Biomarker Panel Has Potential for Alzheimer’s Disease Diagnosis Using Targeted Proteomics and Machine Learning
As disease-modifying therapies are now available for Alzheimer’s disease (AD), accessible, accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to develop a mass spectrometry-based urine test as a high-throughput screening tool for diagnosing AD. We collected urine...
Autores principales: | Hällqvist, Jenny, Pinto, Rui C., Heywood, Wendy E., Cordey, Jonjo, Foulkes, Alexander J. M., Slattery, Catherine F., Leckey, Claire A., Murphy, Eimear C., Zetterberg, Henrik, Schott, Jonathan M., Mills, Kevin, Paterson, Ross W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531486/ https://www.ncbi.nlm.nih.gov/pubmed/37762058 http://dx.doi.org/10.3390/ijms241813758 |
Ejemplares similares
-
CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia
por: Heywood, Wendy E., et al.
Publicado: (2018) -
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology
por: Paterson, R W, et al.
Publicado: (2016) -
‘The long tail of Covid-19’ - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients
por: Doykov, Ivan, et al.
Publicado: (2021) -
Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
por: Heywood, Wendy E., et al.
Publicado: (2016) -
Neurofilament light chain: defining the analyte
por: Leckey, Claire A., et al.
Publicado: (2022)